Hormone metabolism pathway genes and mammographic density change after quitting estrogen and progestin combined hormone therapy in the California Teachers Study

Eunjung Lee; Jianning Luo; Yu-Chen Su; Lewinger, Juan Pablo; Schumacher, Fredrick R.; Van Den Berg, David; Wu, Anna H.; Bernstein, Leslie; Ursin, Giske
December 2014
Breast Cancer Research;2014, Vol. 16 Issue 6, p52
Academic Journal
Introduction Mammographic density (MD) is a strong biomarker of breast cancer risk. MD increases after women start estrogen plus progestin therapy (EPT) and decreases after women quit EPT. A large interindividual variation in EPT-associated MD change has been observed, but few studies have investigated genetic predictors of the EPT-associated MD change. Here, we evaluate the association between polymorphisms in hormone metabolism pathway genes and MD changes when women quit EPT. Methods We collected mammograms before and after women quit EPT and genotyped 405 tagging single nucleotide polymorphism (SNP)s in 30 hormone metabolism pathway genes in 284 non-Hispanic white participants of the California Teachers Study (CTS). Participants were ages 49 to 71 years at time of mammography taken after quitting EPT. We assessed percent MD using a computer-assisted method. MD change was calculated by subtracting MD of an 'off-EPT' mammogram from MD of an 'on-EPT' (that is baseline) mammogram. Linear regression analysis was used to investigate the SNP-MD change association, adjusting for the baseline 'on-EPT' MD, age and BMI at time of baseline mammogram, and time interval and BMI change between the two mammograms. An overall pathway and gene-level summary was obtained using the adaptive ranked truncated product (ARTP) test. We calculated 'Pvalues adjusted for correlated tests (PACT)' to account for multiple testing within a gene. Results The strongest associations were observed for rs7489119 in SLCO1B1, and rs5933863 in ARSC. SLCO1B1 and ARSC are involved in excretion and activation of estrogen metabolites of EPT, respectively. MD change after quitting was 4.2% smaller per minor allele of rs7489119 (P =0.0008; PACT =0.018) and 1.9% larger per minor allele of rs5933863 (P =0.013; PACT =0.025). These individual SNP associations did not reach statistical significance when we further used Bonferroni correction to consider the number of tested genes. The pathway level summary ARTP P-value was not statistically significant. Conclusions Data from this longitudinal study of EPT quitters suggest that genetic variation in two hormone metabolism pathway genes, SLCO1B1 and ARSC, may be associated with change in MD after women stop using EPT. Larger longitudinal studies are needed to confirm our findings.


Related Articles

  • Postmenopausal estrogen-progestin therapy and breast cancer: a clinical response to an epidemiologic report. Speroff, Leon // Contemporary OB/GYN;Mar2000, Vol. 45 Issue 3, p103 

    Analyzes the findings of a study which compared the risks of breast cancer associated with postmenopausal hormone regiments of estrogen alone or a combination of estrogen and progestin. Discussion on the findings of the study; Epidemiologic evidence on the impact of combined estrogen-progestin...

  • SNP 1772 C > T of HIF-1α gene associates with breast cancer risk in a Taiwanese population. Chih-Jen Huang; Shi-Long Lian; Ming-Feng Hou; Chee-Yin Chai; Yi-Hsing Yang; Sheng-Fung Lin; Hsueh-Wei Chang // Cancer Cell International;2014, Vol. 14 Issue 1, p1 

    Background Hypoxia inducible factor 1α (HIF-1α) is a stress-responsive transcription factor to hypoxia and its expression is correlated to tumor progression and angiogenesis. Several single nucleotide polymorphisms (SNPs) of HIF-1α gene in the oxygen-dependent degradation (ODD) domain...

  • Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement.  // Breast Cancer Research;2012, Vol. 14 Issue 1, p3110 

    The article focuses on a case-control study of postmenopausal women that investigated the performance of several prediction models in forecasting risk of breast cancer. The performance of the model based on an initial set of seven breast cancer risk single-nucleotide polymorphisms (SNPs) is...

  • A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density. Rudolph, Anja; Fasching, Peter A.; Behrens, Sabine; Eilber, Ursula; Bolla, Manjeet K.; Qin Wang; Thompson, Deborah; Czene, Kamila; Brand, Judith S.; Jingmei Li; Scott, Christopher; Pankratz, V. Shane; Brandt, Kathleen; Hallberg, Emily; Olson, Janet E.; Lee, Adam; Beckmann, Matthias W.; Ekici, Arif B.; Haeberle, Lothar; Maskarinec, Gertraud // Breast Cancer Research;Aug2015, Vol. 17 Issue 1, p1 

    Introduction: Mammographic density is an established breast cancer risk factor with a strong genetic component and can be increased in women using menopausal hormone therapy (MHT). Here, we aimed to identify genetic variants that may modify the association between MHT use and mammographic...

  • Variation in Inflammatory Cytokine/Growth-Factor Genes and Mammographic Density in Premenopausal Women Aged 50–55. Ozhand, Ali; Lee, Eunjung; Wu, Anna H.; Ellingjord-Dale, Merete; Akslen, Lars A.; McKean-Cowdin, Roberta; Ursin, Giske // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Background: Mammographic density (MD) has been found to be an independent risk factor for breast cancer. Although data from twin studies suggest that MD has a strong genetic component, the exact genes involved remain to be identified. Alterations in stromal composition and the number of...

  • Vitamin D Intake, Month the Mammogram Was Taken and Mammographic Density in Norwegian Women Aged 50–69. Ellingjord-Dale, Merete; dos-Santos-Silva, Isabel; Grotmol, Tom; Kaur Sakhi, Amrit; Hofvind, Solveig; Qureshi, Samera; Skov Markussen, Marianne; Couto, Elisabeth; Vos, Linda; Ursin, Giske // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: The role of vitamin D in breast cancer etiology is unclear. There is some, but inconsistent, evidence that vitamin D is associated with both breast cancer risk and mammographic density (MD). We evaluated the associations of MD with month the mammogram was taken, and with vitamin D...

  • Does new breast pain during HT signal increased BrCa risk?  // Contemporary OB/GYN;Nov2006, Vol. 51 Issue 11, p20 

    The article discusses research being done on the link between breast pain and breast tissue density increase on mammography in postmenopausal women undergoing combination hormone therapy. It references a study by Carolyn J. Crandall and colleagues, published in the 2006 issue of "Archive of...

  • Is Benign Breast Disease a Contraindication for ERT? Miller, Karl // American Family Physician;8/1/1999, Vol. 60 Issue 2, p615 

    Highlights a study of women with benign breast disease established by biopsy to identify a possible link between estrogen replacement therapy and breast cancer risk. Materials; Methodology; Results; Conclusion; Implications.

  • Association of five single nucleotide polymorphisms at 6q25.1 with breast cancer risk in northwestern China. Long Zhou; Na He; Tian Feng; Tingting Geng; Tianbo Jin; Chao Chen // American Journal of Cancer Research;2015, Vol. 5 Issue 8, following p2467 

    CCDC170 and ESR1, located at 6q25.1, were associated with breast cancer (BC) risk by genome-wide association studies. Our goal was to validate the association between CCDC170-ESR1 polymorphisms and BC risk in the population of northwestern China. A case-control study of 551 patients with BC and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics